UNSPSC 51111654: Raltitrexed

This classification denotes a thymidylate synthase inhibitor and folate antagonist with the molecular formula C21H22N4O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FCB9EGG971, chemically known as n-(5-(n-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-n-methylamino)-2-thenoyl)-l-glutamic acid but generally known as raltitrexed, which bears US NIH Compound Identifier 104758. European Medicines Agency schedules Raltitrexed in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10244MIG.

UNSPSC 51111654 Raltitrexed, a Commodity code, maps to state and local pharmacy benefit procurement centered on direct-to-manufacturer prescription programs and pharmaceutical supply management. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 seeking vendor capabilities for establishing direct relationships between the state's pharmacy benefit program and pharmaceutical manufacturers to improve prescription fulfillment efficiency and cost management, signaling active state-level interest in restructuring pharmacy procurement channels outside traditional pharmacy benefit manager, group purchasing organization, and wholesaler arrangements. The solicitation targets vendors with experience in direct contracting for self-insured employers and health plans in both private and government sectors, capacity to negotiate based on net pricing models without rebates, and ability to implement value-based or outcomes-based agreements. The work involves fulfilling product volume requirements, managing dependencies on dedicated pharmacy partners or specialized channel participants, and supporting purchasing organizations serving multiple government jurisdictions or government employee and retiree plans.

State health and human services agencies represent the primary issuing bodies under this code. The Texas HHS Commission's RFI is exploratory in nature, designed to gather market intelligence before issuing a formal RFP with established financial and temporal parameters; no award values, budget ranges, or set-aside designations are specified at this preliminary phase. Recent activity is limited to the Texas solicitation, with no other state or local opportunities in the block to establish broader geographic spread or issuing-body patterns. The RFI response deadline of April 3, 2026 has passed, indicating the state is now in the information-synthesis phase that will inform future formal competitive solicitations.